Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Acoustic neuroma; Haemangioblastoma; Meningioma; Neurilemmoma; Neurofibromatosis 2
- Focus Therapeutic Use
- 26 Feb 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov.
- 26 Feb 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.